Category: Blog
PCR Working and Design Is Not Important
Myth 1: PCR Nearly Always Works and Design Is Not that Important
It might come as a surprise to many that despite the wide use and large investment, PCR in fact is still subject to many artifacts and environmental factors and is not as robust as would be desirable. Many of these artifacts can be avoided by careful oligonucleotide design. Over the last 10 years (1996–2006), I have informally polled scientists who are experts in PCR and asked: “What percentage of the time does a casually designed PCR reaction ‘work’ without any experimental optimization?” In this context, “work” means that the desired amplification product is made in good yield with a minimum of artifact products such as primer dimers, wrong amplicons, or inefficient amplification. By “casually designed,” I mean that typical software tools are used by an experienced molecular biologist. The consensus answer is 70–75%. If one allows for optimization of the annealing temperature in the thermocy- cling protocol (e.g., by using temperature gradient optimization), magnesium concentration optimization, and primer concentration optimization, then the consensus percentage increases to 90–95%. What is a user to do, however, in the 5–10% of cases where single-target PCR fails? Typically, they redesign the primers (without knowledge of what caused the original failure), resyn- thesize the oligonucleotides, and retest the PCR. Such a strategy works fine for laboratories that perform only a few PCRs. Once a particular PCR protocol is tested, it is usually quite reproducible, and this leads to the feeling that PCR is reliable. Even the 90–95% of single-target PCRs that “work” can be improved by using good design principles, which increases the sensitivity, decreases the background amplifications, and requires less experimental optimization. In a high-throughput industrial-scale environment, however, individual optimization of each PCR, redesigning failures, performing individualized thermocycling and buffer conditions, and tracking all these is a nightmare logistically and leads to non-uniform success. In multiplex PCR, all the targets are obviously amplified under the same solution and temperature cycling conditions, so there is no possibility of doing individual optimizations. Instead, it is desirable to have the capability to automatically design PCRs that work under a single general set of conditions without any optimization, which would enable parallel PCRs (e.g., in 384-well format) to be performed under the same buffer conditions and thermocycling protocol. Such robustness would further improve reliability of PCR in all applications but particularly in non-laboratory settings such as hospital clinics or field-testing applications.
Discovery of PCR
Shortly after the discovery of PCR, software for designing oligonucleotides was developed (12). Some examples of widely used primer design software (some of which are described in this book) include VectorNTI, OLIGO (12), Wisconsin GCG, Primer3 (13), PRIMO (14), PRIDE (15), PRIMERFINDER (http://arep.med.harvard.edu/PrimerFinder/PrimerFinderOverview.html), OSP (16), PRIMERMASTER (17), HybSIMULATOR (18), and PrimerPremiere. Many of these programs do incorporate novel features such as accounting for template quality (14) and providing primer predictions that are completely automated (14,15). Each software package has certain advantages and disadvantages, but all are not equal. They widely differ in their ease- of-use, computational efficiency, and underlying theoretical and conceptual framework. These differences result in varying PCR design quality. In addition, there are standalone Web servers that allow for individual parts of PCR to be predicted, notably DNA-MFOLD by Michael Zuker (http://www.bioinfo.rpi.edu/applications/mfold/old/dna/) and HYTHER by my laboratory (http://ozone3.chem.wayne.edu).
Why Is There a Need for Primer Design Software?
DNA hybridization experiments often require optimization because DNA hybridization does not strictly follow the Watson–Crick pairing rules. Instead, a DNA oligonucleotide can potentially pair with many sites on the genome with perhaps only one or a few mismatches, leading to false-positive results. In addition, the desired target sites of single-stranded genomic DNA or mRNA are often folded into stable secondary structures that must be unfolded to allow an oligonucleotide to bind. Sometimes, the target folding is so stable that very little probe DNA binds to the target, leading to a false-negative test. Various other artifacts include probe folding and probe dimerization. Thus, for DNA-based diagnostics to be successful, there is a need to fully understand the science underlying DNA folding and match versus mismatch hybridization. Achieving this goal has been a central activity of my academic laboratory as well as DNA Software, Inc.
Comparison of traditional quantitative pcr with computer quantitation
Comparison of traditional quantitative pcr with a computer-based quantitation algorithm for cmv from plasma specimens
Background
Difference between traditional quantitative pcr with computer-based quantitation algorithm for cmv. Traditional viral quantitation using cycle threshold (Ct) analysis is dependent on generating an accurate, valid calibration curve that is stable over time. The relationship between the Ct values obtained and the expected concentration for each calibrator is used to establish a formula to quantify viral concentrations in patient samples. Additionally, a fluorescence threshold is set to compare amplification cycles as an indirect measure of the starting DNA concentration. DNA Software, Inc. (Ann Arbor, MI) has developed a curve analysis algorithm (qPCR CopyCount) based on Poisson distribution that analyzes qPCR data to obtain an absolute DNA copy number without the need for a standard curve or use of Ct values. Our objectives were to compare the performance of qPCR CopyCount to traditional qPCR (Ct) for the quantitation of CMV from plasma and evaluate its feasibility for daily clinical use in a CMV plasma quantitation assay.
Methods
Fluorescence data from archived runs of our CMV assay, using Abbott ASR reagents on the Abbott m2000 system, were analyzed using CopyCount algorithm. CopyCount quantification was compared to original data using a calibration curve and Ct values. Nucleic acid quantitative standards (Qiagen), calibrators traceable to international units (CMVtc panel, Acrometrix), and patients were compared for linearity, precision, and accuracy.
Results
CopyCount results had a linear relationship with nucleic acid quantitative standard assigned values (r2>0.99; bias of log10 0.2 copies per reaction) and patient results by Ct method (r2>0.99). Raw CopyCount values do not account for extraction efficiency or concentration of the eluate, introducing a systematic bias between methods (bias -1.2 copies/ml). Evaluation of the CopyCount values from the extracted CMVtc panel demonstrated a linear relationship (r2>0.98) and provided a correction factor for extraction efficiency. Using this correction, the relationship between CopyCount and patient values remained linear (r2>0.99) with a reduced bias of log10 0.08 IU/ml. Precision of quantitative standard results (4 standards in duplicate over 10 runs) was a total standard deviation range of 0.05-0.15 log10 copies/rxn for CopyCount vs 0.02-0.16 log10 copies/ml for the current Ct method.
Conclusions
The CopyCount method performed similarly to the conventional Ct method for quantitation of CMV from patient samples and quantitative standards with excellent linearity and comparable precision. A correction factor or formula is required to DNA concentration in the PCR reaction to the concentration in the original specimen. A one-time calibration, using 1.5 copies per reaction as recommended by the software company to optimize the curve analysis formula, may further improve the accuracy of quantitation.
DNA Software releases ThermoBLAST Cloud Edition
DNA Software introduced the full commercial release of ThermoBLAST Cloud Edition (TB-CE). TB-CE provides a new standard for evaluating the target specificity of oligonucleotides.
DNAS gives webinar on qPCR CopyCount
DNAS gives webinar on qPCR CopyCount, click here to view video.
CEO Dr. John SantaLucia presents qPCR CopyCount, in Spain
CEO Dr. John SantaLucia presents qPCR CopyCount and Counting PCR at the 5th World Congress on Biotechnology in Valencia, Spain.
http://www.biotechnologycongress.com
DNAS releases version 1.15 of qPCR CopyCount
DNA Software announces the release of version 1.15 of qPCR CopyCount with features that improve both relative and absolute quantification.
CEO Dr. John SantaLucia presents qPCR CopyCount, in UAE
CEO Dr. John SantaLucia presents qPCR CopyCount and Counting PCR at the 2nd Biotechnology World Congress in Dubai, UAE …. Read More
CEO Dr. John SantaLucia presents qPCR CopyCount launch
CEO Dr. John SantaLucia presents qPCR CopyCount commercial launch at Tri-Con Molecular Medicine Conference in San Francisco …. Read More
DNA Software presents at Digital PCR conference
DNA Software presents at Digital PCR conference
“Counting PCR”: Absolute DNA Copy Number without Standards” by John SantaLucia, Jr., Ph.D.; President & CEO, DNA Software, Inc.
qPCR CopyCountTM is a software tool that fits raw qPCR data using mechanism-based modeling to determine highly accurate relative and absolute DNA concentrations without the use of standards, without specialized equipment, and without digital PCR. qPCR CopyCountTM has applications in non-invasive diagnostics for copy number variation, gene expression analysis, and genotyping in cancer screening, fetal testing, and agriculture.
DNAS in Rare Genome Institute Science Challenge
DNA Software participates in Rare Genome Institute Science Challenge…Read More